Cardiovascular disease in rheumatoid arthritis

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Rheumatoid arthritis (RA) is associated with significant cardiac complications, such as pericarditis, valvular disease, cardiomyopathy, and amyloidosis.
• Subclinical cardiac involvement is common in RA patients, often appearing early in the disease course.
• Cardiovascular disease (CVD) prevalence is high in RA, influenced by disease-specific factors.

Purpose of the Study:

• To highlight the spectrum of cardiac complications in RA.
• To emphasize the prevalence and early onset of CVD in RA.
• To discuss disease-specific risk factors and modified cardiovascular risk assessment in RA.

Main Methods:

• Review of existing literature on RA and cardiac complications.
• Analysis of disease-specific risk factors implicated in RA-associated CVD.
• Evaluation of current cardiovascular risk assessment strategies in RA patients.
• Assessment of therapeutic interventions for dyslipidemia and CVD risk reduction in RA.

Main Results:

• RA patients face diverse cardiac issues, including pericarditis, valvular disease, cardiomyopathy, and amyloidosis, with high rates of subclinical involvement.
• Cardiovascular disease is prevalent in RA, manifesting early and influenced by factors like seropositivity, disease activity, and medications.
• Traditional cardiovascular risk factors (e.g., BMI, lipids) may differ in their impact on RA patients.
• Statins are effective for dyslipidemia in RA, and methotrexate and TNF inhibitors show promise for CVD risk reduction with disease control.

Conclusions:

• RA patients have a high burden of cardiac complications, necessitating vigilant monitoring.
• Cardiovascular risk assessment and management in RA require a personalized approach, considering disease-specific factors.
• Effective management of RA disease activity is crucial for mitigating cardiovascular risk.